JP2012184264A5 - - Google Patents

Download PDF

Info

Publication number
JP2012184264A5
JP2012184264A5 JP2012148640A JP2012148640A JP2012184264A5 JP 2012184264 A5 JP2012184264 A5 JP 2012184264A5 JP 2012148640 A JP2012148640 A JP 2012148640A JP 2012148640 A JP2012148640 A JP 2012148640A JP 2012184264 A5 JP2012184264 A5 JP 2012184264A5
Authority
JP
Japan
Prior art keywords
composition
administered
subject
dose
viral infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012148640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012184264A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012184264A publication Critical patent/JP2012184264A/ja
Publication of JP2012184264A5 publication Critical patent/JP2012184264A5/ja
Withdrawn legal-status Critical Current

Links

JP2012148640A 2004-06-24 2012-07-02 免疫増強用の化合物 Withdrawn JP2012184264A (ja)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US58265404P 2004-06-24 2004-06-24
US60/582,654 2004-06-24
US58809604P 2004-07-14 2004-07-14
US60/588,096 2004-07-14
US59045904P 2004-07-22 2004-07-22
US60/590,459 2004-07-22
US59959204P 2004-08-05 2004-08-05
US59971704P 2004-08-05 2004-08-05
US60/599,717 2004-08-05
US60/599,592 2004-08-05
US60085004P 2004-08-11 2004-08-11
US60/600,850 2004-08-11
US60300104P 2004-08-19 2004-08-19
US60/603,001 2004-08-19
US60386704P 2004-08-23 2004-08-23
US60/603,867 2004-08-23
US61207004P 2004-09-21 2004-09-21
US60/612,070 2004-09-21
US61496304P 2004-09-30 2004-09-30
US60/614,963 2004-09-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007518351A Division JP2008504292A (ja) 2004-06-24 2005-06-24 免疫増強用の化合物

Publications (2)

Publication Number Publication Date
JP2012184264A JP2012184264A (ja) 2012-09-27
JP2012184264A5 true JP2012184264A5 (enExample) 2012-11-08

Family

ID=35601821

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007518351A Withdrawn JP2008504292A (ja) 2004-06-24 2005-06-24 免疫増強用の化合物
JP2012148640A Withdrawn JP2012184264A (ja) 2004-06-24 2012-07-02 免疫増強用の化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007518351A Withdrawn JP2008504292A (ja) 2004-06-24 2005-06-24 免疫増強用の化合物

Country Status (4)

Country Link
EP (2) EP2277595A3 (enExample)
JP (2) JP2008504292A (enExample)
CA (1) CA2571421A1 (enExample)
WO (1) WO2006002422A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504286A (ja) * 2004-06-24 2008-02-14 カイロン コーポレイション 小分子免疫増強因子およびその検出のためのアッセイ
CN1947717B (zh) * 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
US10842867B2 (en) 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628206A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
JP2009515839A (ja) * 2005-11-15 2009-04-16 メルク フロスト カナダ リミテツド ステアロイル−CoAデルタ−9デサチュラーゼ阻害剤としてのアザシクロヘキサン誘導体
ES2531623T3 (es) * 2005-12-13 2015-03-18 Mcgill University Fenretinida para corregir un desequilibrio de lípidos en un sujeto
JP2009520730A (ja) 2005-12-23 2009-05-28 ヤド・テヒノロギース・ゲーエムベーハー アレルギー性疾患を治療および予防するための手段および方法
HUE049580T2 (hu) 2006-01-27 2020-09-28 Seqirus Uk Ltd Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US8158810B2 (en) 2006-07-27 2012-04-17 Gilead Sciences, Inc. ALDH-2 inhibitors in the treatment of addiction
WO2008014497A2 (en) * 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
CN101594870A (zh) * 2006-08-22 2009-12-02 康塞特医药品有限公司 4-氨基喹唑啉衍生物及其使用方法
ES3031467T3 (en) 2006-09-11 2025-07-09 Seqirus Uk Ltd Making influenza virus vaccines without using eggs
US8198266B2 (en) 2006-10-31 2012-06-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of an EGFR antagonist for the treatment of glomerolonephritis
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2687338A1 (en) * 2007-05-23 2008-11-27 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2008269439B2 (en) 2007-06-27 2013-12-19 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN101925590A (zh) * 2008-01-24 2010-12-22 吉利德帕洛阿尔托股份有限公司 治疗成瘾的aldh-2抑制剂
ES2326459B1 (es) * 2008-04-08 2010-05-28 Universidad De Oviedo Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos.
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
JP2012503619A (ja) * 2008-09-26 2012-02-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Hcv感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ
US8809343B2 (en) 2008-12-26 2014-08-19 Fudan University Pyrimidine derivative, preparation method and use thereof
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
BR112012026644A2 (pt) * 2010-04-23 2017-12-19 Kineta Inc compostos antivirais
WO2012064981A2 (en) * 2010-11-10 2012-05-18 National Jewish Health Methods to test allergic conditions
CN102552271B (zh) * 2010-12-09 2014-08-06 中国科学院上海药物研究所 一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途
HRP20190791T1 (hr) 2011-01-26 2019-06-28 Glaxosmithkline Biologicals Sa Režim imuniziranja protiv rsv
EP2918273B1 (en) * 2011-02-25 2016-12-21 Kineta, Inc. Methods and cells for identifying rig-i pathway regulators
PT3275892T (pt) 2011-05-13 2020-04-08 Glaxosmithkline Biologicals Sa Antigénios f de rsv de pré-fusão
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2016046734A2 (en) * 2014-09-22 2016-03-31 University Of The Western Cape Compounds and compositions for treatment of tuberculosis
DE102014017368A1 (de) 2014-11-24 2015-05-28 Clariant International Ltd. Verwendung von Polyhydroxyfettsäureamiden zur Verbesserung der Nassabriebbeständigkeit von wässrigen Dispersionsfarben
DE202014010366U1 (de) 2014-11-24 2015-05-15 Clariant International Ltd. Verwendung von Polyhydroxyfettsäureamiden zur Verbesserung der Nassabriebbeständigkeit von wässrigen Dispersionen
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
CN109223795B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物b2作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109223793B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物c1作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109223796B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物b6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN108853110B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109223794B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109053544B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物b11作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109232573A (zh) * 2018-08-24 2019-01-18 江苏理工学院 一种化合物b1作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109400567A (zh) * 2018-12-05 2019-03-01 华中药业股份有限公司 一种合成甘草素的方法
EP3725788A1 (en) 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
CN112125940B (zh) * 2020-10-31 2025-10-21 青岛姿之妍化妆品科技有限责任公司 含有四乙酰葡萄糖苷改性的根皮素的化妆品及其制备方法
CN112300228A (zh) * 2020-10-31 2021-02-02 青岛姿之妍化妆品科技有限责任公司 一种包括含有根皮三酚基团的根皮素衍生物的化妆品及其制备方法
CN119859132A (zh) * 2023-10-20 2025-04-22 中国石油化工股份有限公司 一种环烃类白杨素衍生物及其制备方法
CN118580289B (zh) * 2024-06-21 2025-05-13 海南大学 一种具有抗肿瘤作用的化合物bp220805及其制备方法和应用

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567431A (enExample) 1957-05-07
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
EP0273512B1 (en) 1986-12-19 1991-02-27 Duphar International Research B.V Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
EP0283085B1 (en) 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
JP2766360B2 (ja) 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
IL89167A (en) 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2011896C (en) 1989-04-21 2001-05-08 Mark Werner Ringworm vaccine
EP0474727B1 (en) 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ATE207958T1 (de) 1989-08-04 2001-11-15 Schering Ag Äusserliche domäne von c-erbb-2:gp75
US5439936A (en) 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5284652A (en) 1990-10-26 1994-02-08 Pier Allan C Dermatophyte vaccine
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0540185A1 (en) 1991-10-10 1993-05-05 Schering Corporation 4'-(N-substituted-N-oxide)staurosporine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
JPH07505124A (ja) 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア ニューロトロフィン活性増強のためのk−252化合物を含む組成物
CA2117303C (en) 1991-11-29 2000-10-17 Sunil Chada Anti-cancer immunotherapeutic vector constructs
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993018150A1 (en) 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
DE69331228D1 (en) 1992-09-21 2002-01-10 Kyowa Hakko Kogyo Kk Heilmittel für thrombozytopenia
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
ES2149276T3 (es) 1993-07-15 2000-11-01 Minnesota Mining & Mfg Imidazo(4,5-c)piridin-4-aminas.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
WO1995017182A1 (en) 1993-12-23 1995-06-29 Eli Lilly And Company Protein kinase c inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5554519A (en) 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
AU6888196A (en) 1995-08-11 1997-03-12 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
EA000710B1 (ru) 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
JP2000511769A (ja) 1996-04-02 2000-09-12 スミスクライン・ビーチャム・コーポレイション 新規化合物
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
WO1997043303A1 (en) 1996-05-14 1997-11-20 Smithkline Beecham Corporation Novel compounds
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
CA2264496C (en) 1996-09-04 2008-10-07 Takara Shuzo Co., Ltd. Fungal antigens and process for producing the same
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
AU5194598A (en) 1996-10-31 1998-05-22 Human Genome Sciences, Inc. (streptococcus pneumoniae) antigens and vaccines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
CA2293489C (en) 1997-06-06 2009-09-29 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
ES2253821T3 (es) 1997-07-12 2006-06-01 Cancer Research Technology Limited Derivados de purina inhibidores de quinasa que depende de ciclina.
US5948413A (en) 1997-07-17 1999-09-07 Board Of Trustees Operating Michigan State University Method and vaccine for treatment of pythiosis insidiosi in humans and lower animals
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
DE69836977T2 (de) 1997-11-21 2007-10-18 Serono Genetics Institute S.A. Chlamydia pneumoniae genomische sequenzen und polypeptiden, fragmenten und anwendungen davon für nachweis, prevention und heilung
CN1280619A (zh) 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
TR200003514T2 (tr) 1998-05-29 2002-05-21 Sugen Inc. Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
WO2000018769A2 (en) 1998-09-30 2000-04-06 Wrair (Walter Reid Army Institute Of Research) INDOLO[2,1-b]QUINAZOLE-6,12-DIONE ANTIMALARIAL COMPOUNDS AND METHODS OF TREATING MALARIA THEREWITH
MXPA01003557A (es) 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
CA2773698C (en) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
MY125202A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
EP1187629B1 (en) 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2000067161A2 (en) 1999-05-04 2000-11-09 Grant Lee H Method and apparatus for categorizing and retrieving network pages and sites
EP1201668A4 (en) 1999-07-13 2003-05-21 Kyowa Hakko Kogyo Kk Staurosporine DERIVATIVES
WO2001008636A2 (en) 1999-08-03 2001-02-08 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
HK1046861A1 (zh) 1999-09-24 2003-01-30 Smithkline Beecham Biologicals S.A. 包括聚氧乙烯烷基酯或者醚以及至少一種非離子表面活性劑的佐劑
EP1676845B1 (en) * 1999-11-05 2008-06-11 AstraZeneca AB New quinazoline derivatives
ATE476988T1 (de) 2000-01-17 2010-08-15 Novartis Vaccines & Diagnostic Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
BRPI0117360B8 (pt) 2000-02-15 2021-07-06 Upjohn Co inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
EP1274718B1 (en) 2000-04-12 2006-10-18 Genaera Corporation A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
KR100815681B1 (ko) 2000-06-30 2008-03-20 글락소 그룹 리미티드 퀴나졸린 디토실레이트 염 화합물
BR0113356A (pt) * 2000-08-18 2004-04-20 Millennium Pharm Inc Derivados de quinazolina como inibidores de quinase
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
ES2330083T3 (es) 2000-10-27 2009-12-04 Novartis Vaccines And Diagnostics S.R.L. Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
CA2447599C (en) 2001-05-18 2015-04-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
EP1404689A1 (en) 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
US6900342B2 (en) 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
PT1551357E (pt) 2002-09-13 2014-10-10 Novartis Vaccines & Diagnostic Vacina contra os estreptococos do grupo b
AU2003264488A1 (en) * 2002-09-19 2004-04-08 Orient Cancer Therapy Co., Ltd. Immunotherapeutic for cancer
JP4896715B2 (ja) 2003-06-26 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Chlamydiatrachomatisに対する免疫原性組成物
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes

Similar Documents

Publication Publication Date Title
JP2012184264A5 (enExample)
JP2017537066A5 (enExample)
JP2019526596A5 (enExample)
JP2015157821A5 (enExample)
WO2018209324A3 (en) Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
Lei et al. Socioeconomic status and chronic diseases: The case of hypertension in China
JP2017525730A5 (enExample)
TR201908199T4 (tr) HPV'ye karşı aşılar.
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
JP2015505296A5 (enExample)
JP2013241424A5 (enExample)
JP2014509612A5 (enExample)
JP2020097577A5 (enExample)
JP2016510326A5 (enExample)
JP2011246469A5 (enExample)
RU2015114543A (ru) Способы лечения гепатита с
JP2015514115A5 (enExample)
JP2016128507A5 (enExample)
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
JP2017532316A5 (enExample)
NZ629255A (en) A novel drug delivery system based on jcv-vlp
EA201170264A1 (ru) Вакцина против hpv
JP2013515490A5 (enExample)
JP2016500703A5 (enExample)